Trial Profile

Safety and Efficacy of Gemtuzumab Ozogamicin (Mylotarg) as for Treatment of Patients With CD33-Positive Acute Myeloid Leukemia (AML)

Status: Withdrawn prior to enrolment

Phase of Trial: Phase II

Latest Information Update: 17 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Gemtuzumab ozogamicin (Primary)
Indications Acute biphenotypic leukaemia; Acute myeloid leukaemia; Acute promyelocytic leukaemia
Focus Adverse reactions

Most Recent Events

28 Jul 2017 Planned End Date changed from 1 Mar 2018 to 1 Sep 2013.
28 Jul 2017 Planned primary completion date changed from 1 Mar 2018 to 1 Sep 2013.
23 Sep 2013 Status changed from suspended to withdrawn prior to recruitment as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com